Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | ATRC AtriCure, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $58.10 -1.7% | $15.06 -2.0% |
| StockIQ Score | 65B- Moderate Risk: Medium | 36F Weak Risk: Medium |
| Technical | 82A- | 13F |
| Fundamental | 39F | 35F |
| Growth | 79B+ | 50C- |
| Fair Value | 38F | 38F |
| News | 100A+ | 50C- |
| Quality | 63C+ | 50C- |
| Risk | 54C- | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
AtriCure (ATRC) outperforms Ascentage Pharma (AAPG) in nearly every category. ATRC has a stronger investor score (66 vs. 37), technical score (87 vs. 18), and growth score (79 vs. 50), while AAPG’s weak rating and lower technical score indicate more risk. Both share the same valuation score of 38, but ATRC’s higher overall scores suggest it’s the stronger pick based on these metrics.